Neurocrine Biosciences Inc. (NBIX)
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NBIX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $14.58B
- P/E (TTM)
- 21.04
- Forward P/E
- 12.08
- EPS (TTM)
- $6.82
- Dividend yield
- None
- 52-week range
- 122.14 – 186.12
- Day range
- 143.21 – 145.88
- Volume / Avg
- 1.08M / 1.30M
- Beta
- —
- Shares outstanding
- 101.65M
- Next earnings
- Oct 27, 2026
52-week range
NBIX stock today
On Oct 7, NBIX ended the session at $143.47, shedding $2.04 (1.40%), versus the S&P 500's 0.22% decline. Shares are 22.9% below their 52-week high of $186.12, set on Jul 30, 2026 and 17.5% above the 52-week low of $122.14, in the middle of the past year's range. NBIX is up 1.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 4.7%.
At 21.0x trailing earnings, Neurocrine Biosciences trades below the peer-group median of 40.7x. Its forward P/E of 12.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of $1.99.
Summary generated from market data by MetaCap's automated system. Methodology
About Neurocrine Biosciences
Company profileNeurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Kyle W. Gano Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 2,500
- IPO year
- 1996
- Website
- neurocrine.com
Financial highlights
Full financialsIn fiscal 2025, Neurocrine Biosciences generated $2.86 billion in revenue, up 21.4% from fiscal 2024, its 9th consecutive year of revenue growth. Net income was $478.6 million (+40.2% year over year), for a net margin of 16.7% versus a median of 13.2% in the prior 5 years. Gross margin was 98.2% (down from 98.6%) and operating margin 21.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Growth | +21.45% | +24.81% | +26.76% | +31.34% | +8.38% |
| Net income | $478.60M | $341.30M | $249.70M | $154.50M | $89.60M |
| EPS (diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
Analyst forecast
ForecastConsensus (29 analysts)
strong_buy
Avg. price target
$207.29+44.48%
- Strong buy 4
- Buy 21
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $1.99
- Last reported (Q2 2026)
- Jul 31, 2026
- EPS actual vs est.
- $1.39 vs —
Neurocrine Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EXELExelixis Inc. | 58.44 | +0.19% | $14.48B | vs NBIX |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs NBIX |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs NBIX |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs NBIX |
| IBRXImmunityBio Inc. | 9.75 | +0.62% | $10.33B | vs NBIX |
| TWSTTwist Bioscience Corporation | 155.65 | -6.78% | $10.32B | vs NBIX |
| PCVXVaxcyte Inc. | 66.96 | +0.39% | $9.96B | vs NBIX |
| KRYSKrystal Biotech Inc. | 324.57 | -0.69% | $9.61B | vs NBIX |
Indexes, lists and sector
Neurocrine Biosciences stock FAQ
What is Neurocrine Biosciences's stock price today?
NBIX last traded at $143.47 as of Oct 7, 4:00 PM EDT, down 1.40% on the day. Prices are delayed at least 15 minutes.
When is Neurocrine Biosciences's next earnings date?
Neurocrine Biosciences is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $1.99.
What is NBIX's P/E ratio?
NBIX trades at a trailing P/E ratio of 21.04 and a forward P/E of 12.08, compared with a median of 40.7 for its closest peers.
Who is Neurocrine Biosciences's CEO?
Mr. Kyle W. Gano Ph.D. is the chief executive officer of Neurocrine Biosciences Inc., which has about 2,500 employees.
What is the NBIX 52-week high?
The 52-week high for NBIX is $186.12 and the 52-week low is $122.14. The stock is currently 22.9% below its high.